Answers are grounded in this paper and cite their sources.
Background Neuromyelitis optica spectrum disorder (NMOSD) is a rare spectrum autoimmune disease of the central nervous system, primarily characterized by recurrent episodes of severe optic neuritis and myelitis. Area postrema syndrome (APS) is a common manifestation of NMOSD that is often misdiagnosed initially. Myasthenia gravis (MG) is another uncommon autoimmune disease that occasionally coexists with NMOSD. To date, there are no approved therapies specifically for NMOSD coexists with autoimmune disease. Inebilizumab is a humanized anti-CD19 monoclonal antibody used to treat autoimmune diseases associated with CD19-positive B cells. The first global approval of inebilizumab for the treatment of adult patients with aquaporin-4 antibody (AQP4)-IgG-seropositive NMOSD was announced in June 2020. Case presentation We present two patients with AQP4-IgG-positive NMOSD and coexisting autoimmune disease. One patient presented with APS and coexisting systemic lupus erythematosus (SLE), and the other had established, clinically stable NMOSD and newly diagnosed acetylcholine receptor (AChR)-IgG-positive generalized MG. Both patients showed significant clinical improvement following treatment with inebilizumab, and no relapse has been recorded to date. Conclusion The two cases highlight the potential efficacy of inebilizumab in the treatment of NMOSD. The findings suggest that inebilizumab may be an effective therapeutic option for patients with NMOSD, particularly those who are seropositive for AQP4-IgG or have coexisting autoimmune diseases.
No takes yet. Share an insight, caveat, or question.
Mu et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: